Email Us
View Reports

Europe POCT Device Market Analysis | Industry Outlook and Forecast 2017 to 2024

  • ID : 673408250  |  
  • Published : Oct-2017  |  
  • Region : Europe  |  
  • Pages : 150   |  
  • Publisher : Data Bridge Market Research

Europe POCT device market is expected to reach USD 11.69 billion by 2024 from USD 6.05 billion in 2016, at a CAGR of 8.6% in the forecast period 2017 to 2024.

Based on geography, the Europe POCT device market is segmented into 11 geographical regions, such as,

Germany,

France,

United Kingdom,

Italy,

Spain,

Russia,

Turkey,

Belgium,

Netherlands,

Switzerland and

Rest of Europe.

Europe POCT device market competition by top players including –

Abbott

Alere Inc.

F. Hoffmann la roche Diagnostics Limited

Siemens AG

Becton, Dickinson and Company

Johnson & Johnson Services Inc.

PTS Diagnostics

Instrumentation Laboratory

Nova Biomedical

Beckman Coulter, Inc.

The Europe POCT device market is segmented on the basis of product type, prescription mode, distribution channel, end user, and geography.

The Europe POCT device market is segmented into twelve types, namely blood glucose testing kits, cardio metabolic monitoring kits, infectious disease testing kits, cholesterol testing kits, pregnancy and fertility tests kits, tumor/cancer markers, urinalysis testing kits, cholesterol test strips, hematology testing kits, drugs of abuse testing kits, fecal occult testing kits, rapid coagulation testing kits, and others.

Cardiometabolic monitoring kits are further segmented into cardiac markers, blood gas/electrolytes testing kits, HbA1c testing kits, and lipids testing.

Also, infectious disease testing kits are further segmented into influenza testing kits, HIV testing kits, hepatitis C testing kits, sexually-transmitted diseases testing kits, tropical diseases testing kits, healthcare-associated infections, and respiratory infections testing kit.

Cholesterol testing kits are further divided into prothrombin time testing kits and activated clotting time testing kit.

On the basis of prescription mode, the Europe point-of-care testing market is segmented into prescription based testing and over-the-counter (OTC) testing.

On the basis of distribution channel, the Europe point-of-care testing market is segmented into direct tenders and retail.

On the basis of end users, the Europe point-of-care testing market is segmented into hospital, clinics, ambulatory care, home healthcare, and research laboratory.

TABLE OF CONTENTS

1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY

1.2. MARKET DEFINITION

1.3. OVERVIEW OF EUROPE POINT-OF-CARE TESTING MARKET

1.4. CURRENCY AND PRICING

1.5. LIMITATION

1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED

2.2. GEOGRAPHIC SCOPE

2.3. YEARS CONSIDERED FOR THE STUDY

2.4. CURRENCY AND PRICING

2.5. RESEARCH METHODOLOGY

2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7. SECONDARY SOURC

2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.1.1. GROWING GERIATRIC POPULATION

3.1.2. ADVANCEMENT IN TECHNOLOGY

3.1.3. DECENTRALIZED LABORATORY TESTING

3.1.4. INCREASED INCIDENCE OF CHRONIC DISEASES

3.1.5. LABORATORY STAFF SHORTAGES

3.2. RESTRAINTS

3.2.1. UNFAVOURABLE REIMBURSEMENT SCENARIO

3.2.2. ECONOMIC COST

3.3. OPPORTUNITIES

3.3.1. EMERGING MICROFLUIDIC LAB-ON-A-CHIP TECHNOLOGY

3.3.2. EMERGING MARKETS

3.3.3. UNMET MEDICAL NEEDS

3.4. CHALLENGES

3.4.1. LACK OF ACCURACY AND EFFICIENCY

3.4.2. DATA MANAGEMENT AND LACK OF CONNECTIVITY

3.4.3. TESTING PERFORMED BY NON-LABORATORY PERSONNEL AND LACK OF AWARENESS AMONG THE USERS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. EUROPE POINT-OF-CARE TESTING MARKET: REGULATORY SCENARIO

6.1. OVERVIEW:

6.1.1. REGULATORY PROCEDURE:

7. EUROPE POINT-OF-CARE TESTING MARKET: REIMBURSEMENT SCENARIO

7.1. OVERVIEW:

8. EUROPE POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE

8.1. OVERVIEW

8.2. CARDIOMETABOLIC MONITORING KITS

8.2.1. CARDIAC MARKERS

8.2.2. BLOOD GAS ELECTROLYTE TESTING KITS

8.2.3. HBA1C TESTING KITS

8.2.4. LIPID TESTING KITS

8.3. INFECTIOUS DISEASE TESTING KITS

8.3.1. INFLUENZA TESTING KITS

8.3.2. HIV TESTING KITS

8.3.3. HEPATITIS TESTING KITS

8.3.4. STD TESTING KITS

8.3.5. TROPICAL DISEASESTESTING KITS

8.3.6. HEALTHCARE ASSOCIATED TESTING KITS

8.3.7. RESPIRATORY INFECTIONS TESTING KITS

8.4. CHOLESTEROL TESTING KITS

8.4.1. PROTHROMBIN TIME TESTING KITS

8.4.2. ACTIVATED CLOTTING TIME TESTING KITS

8.5. BLOOD GLUCOSE TESTING KITS

8.6. PREGNANCY AND FERTILITY TESTING KITS

8.7. TUMOR CANCER MARKERS

8.8. URINALYSIS TESTING KITS

8.9. HEMATOLOGY TESTING KITS

8.10. DRUGS OF ABUSE TESTING KITS

8.11. FECAL OCCULT TESTING KITS

8.12. RAPID COAGULATION TESTING KITS

9. EUROPE POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL

9.1. OVERVIEW

9.1.1. DIRECT TENDER

9.1.2. RETAIL PHARMACY

10. EUROPE POINT-OF-CARE TESTING MARKET, BY END USER

10.1. OVERVIEW

10.2. EUROPE POCT MARKET: HOSPITALS

10.3. EUROPE POCT MARKET: CLINICS

10.4. EUROPE POCT MARKET: AMBULATORY CARE

10.5. EUROPE POCT MARKET: HOME HEALTHCARE

10.6. EUROPE POCT MARKET: RESEARCH LABORATORIES

11. EUROPE POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE

11.1. OVERVIEW

11.2. EUROPE POCT MARKET: PRESCRIPTION BASED TESTING KITS

11.3. EUROPE POCT MARKET: OVER THE COUNTER BASED TESTING KITS

12. EUROPE POINT-OF-CARE TESTING MARKET, BY GEOGRAPHY

12.1. OVERVIEW

12.2. EUROPE POINT-OF-CARE TESTING MARKET

12.2.1. GERMANY POINT-OF-CARE TESTING MARKET

12.2.2. FRANCE POINT-OF-CARE TESTING MARKET

12.2.3. U.K. POINT-OF-CARE TESTING MARKET

12.2.4. ITALY POINT-OF-CARE TESTING MARKET

12.2.5. SPAIN POINT-OF-CARE TESTING MARKET

12.2.6. RUSSIA POINT-OF-CARE TESTING MARKET

12.2.7. TURKEY POINT-OF-CARE TESTING MARKET

12.2.8. BELGIUM POINT-OF-CARE TESTING MARKET

12.2.9. NETHERLANDS POINT-OF-CARE TESTING MARKET

12.2.10. SWITZERLAND POINT-OF-CARE TESTING MARKET

12.2.11. REST OF EUROPE POINT-OF-CARE TESTING MARKET

13. EUROPE POINT-OF-CARE TESTING MARKET : COMPANY LANDSCAPE

13.1. COMPANY SHARE ANALYSIS: EUROPE

13.2. COMPANY SHARE ANALYSIS: NORTH AMERICA

13.3. COMPANY SHARE ANALYSIS: EUROPE

13.4. COMPANY SHARE ANALYSIS: APAC

14. COMPANY PROFILES

14.1. JOHNSON AND JOHNSON SERVICES, INC.

14.1.1. COMPANY OVERVIEW

14.1.2. REVENUE ANALYSIS

14.1.3. PRODUCT PORTFOLIO

14.1.4. RECENT DEVELOPMENTS

14.2. BECTON, DICKINSON AND COMPANY

14.2.1. COMPANY OVERVIEW

14.2.2. REVENUE ANALYSIS

14.2.3. PRODUCT PORTFOLIO

14.2.4. RECENT DEVELOPMENTS

14.3. MEDTRONIC

14.3.1. COMPANY OVERVIEW

14.3.2. REVENUE ANALYSIS

14.3.3. PRODUCT PORTFOLIO

14.3.4. RECENT DEVELOPMENTS

14.4. F. HOFFMANN-LA ROCHE LTD

14.4.1. COMPANY OVERVIEW

14.4.2. REVENUE ANALYSIS

14.4.3. PRODUCT PORTFOLIO

14.4.4. RECENT DEVELOPMENTS

14.5. SIEMENS AG

14.5.1. COMPANY OVERVIEW

14.5.2. REVENUE ANALYSIS

14.5.3. PRODUCT PORTFOLIO

14.5.4. RECENT DEVELOPMENTS

14.6. ABBOTT

14.6.1. COMPANY OVERVIEW

14.6.2. REVENUE ANALYSIS

14.6.3. PRODUCT PORTFOLIO

14.6.4. PRODUCT PIPELINE

14.6.5. RECENT DEVELOPMENTS

14.7. DANAHER

14.7.1. COMPANY OVERVIEW

14.7.2. REVENUE ANALYSIS

14.7.3. PRODUCT PORTFOLIO

14.7.4. RECENT DEVELOPMENTS

14.8. WERFENLIFE

14.8.1. COMPANY OVERVIEW

14.8.2. REVENUE ANALYSIS

14.8.3. PRODUCT PORTFOLIO

14.8.4. RECENT DEVELOPMENTS

14.9. HENRY SCHEIN, INC.

14.9.1. COMPANY OVERVIEW

14.9.2. REVENUE ANALYSIS

14.9.3. PRODUCT PORTFOLIO

14.9.4. RECENT DEVELOPMENTS

14.10. OPTI MEDICAL (SUBSIDIARY OF IDEXX LABORATORIES, INC)

14.10.1. COMPANY OVERVIEW

14.10.2. REVENUE ANALYSIS

14.10.3. PRODUCT PORTFOLIO

14.10.4. RECENT DEVELOPMENTS

14.11. SIENCO, INC.

14.11.1. COMPANY OVERVIEW

14.11.2. REVENUE ANALYSIS

14.11.3. PRODUCT PORTFOLIO

14.11.4. RECENT DEVELOPMENTS

14.12. ACON LABORATORIES, INC.

14.12.1. COMPANY OVERVIEW

14.12.2. REVENUE ANALYSIS

14.12.3. PRODUCT PORTFOLIO

14.12.4. RECENT DEVELOPMENTS

14.13. ATIVA MEDICAL CORPORATION

14.13.1. COMPANY OVERVIEW

14.13.2. REVENUE ANALYSIS

14.13.3. PRODUCT PORTFOLIO

14.13.4. RECENT DEVELOPMENTS

14.14. ABAXIS

14.14.1. COMPANY OVERVIEW

14.14.2. REVENUE ANALYSIS

14.14.3. PRODUCT PORTFOLIO

14.14.4. RECENT DEVELOPMENTS

14.15. ARKRAY, INC

14.15.1. COMPANY OVERVIEW

14.15.2. REVENUE ANALYSIS

14.15.3. PRODUCT PORTFOLIO

14.15.4. RECENT DEVELOPMENTS

14.16. AERSCHER DIAGNOSTICS, LLC

14.16.1. COMPANY OVERVIEW

14.16.2. REVENUE ANALYSIS

14.16.3. PRODUCT PORTFOLIO

14.16.4. RECENT DEVELOPMENTS

14.17. ARTRON LABORATORIES, INC.

14.17.1. COMPANY OVERVIEW

14.17.2. REVENUE ANALYSIS

14.17.3. PRODUCT PORTFOLIO

14.17.4. RECENT DEVELOPMENTS

14.18. BIOMERIEUX SA

14.18.1. COMPANY OVERVIEW

14.18.2. REVENUE ANALYSIS

14.18.3. PRODUCT PORTFOLIO

14.18.4. RECENT DEVELOPMENTS

14.19. ENTOPSIS

14.19.1. COMPANY OVERVIEW

14.19.2. REVENUE ANALYSIS

14.19.3. PRODUCT PORTFOLIO

14.19.4. RECENT DEVELOPMENTS

14.20. LIFESIGN, LLC.

14.20.1. COMPANY OVERVIEW

14.20.2. REVENUE ANALYSIS

14.20.3. PRODUCT PORTFOLIO

14.20.4. RECENT DEVELOPMENTS

15. RELATED REPORTS

TABLE LIST

TABLE 1 EUROPE POINT-OF-CARE TESTING MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION)

TABLE 2 EUROPE POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 3 EUROPE CARDIOMETABOLIC MONITORING POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024 (USD MILLION)

TABLE 4 EUROPE INFECTIOUS DISEASE POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024 (USD MILLION)

TABLE 5 EUROPE CHOLESTEROL POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024 (USD MILLION)

TABLE 6 EUROPE POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE 2015 – 2024 (USD MILLION)

TABLE 7 EUROPE POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION)

TABLE 8 EUROPE POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION)

TABLE 9 GERMANY POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 10 GERMANY POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE 2015 – 2024 (USD MILLION)

TABLE 11 GERMANY POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION)

TABLE 12 GERMANY POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION)

TABLE 13 FRANCE POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 14 FRANCE POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE , 2015 – 2024 (USD MILLION)

TABLE 15 FRANCE POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION)

TABLE 16 FRANCE POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION)

TABLE 17 U.K. POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 18 U.K. POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION)

TABLE 19 U.K. POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION)

TABLE 20 U.K. POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION)

TABLE 21 ITALY POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 22 ITALY POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION)

TABLE 23 ITALY POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION)

TABLE 24 ITALY POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION)

TABLE 25 SPAIN POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 26 SPAIN POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION)

TABLE 27 SPAIN POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION)

TABLE 28 SPAIN POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION)

TABLE 29 RUSSIA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 30 RUSSIA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION)

TABLE 31 RUSSIA POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION)

TABLE 32 RUSSIA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION)

TABLE 33 TURKEY POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 34 TURKEY POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION)

TABLE 35 TURKEY POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION)

TABLE 36 TURKEY POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION)

TABLE 37 BELGIUM POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 38 BELGIUM POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION)

TABLE 39 BELGIUM POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION)

TABLE 40 BELGIUM POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION)

TABLE 41 NETHERLANDS POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 42 NETHERLANDS POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION)

TABLE 43 NETHERLANDS POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION)

TABLE 44 NETHERLANDS POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION)

TABLE 45 SWITZERLAND POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 46 SWITZERLAND POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION)

TABLE 47 SWITZERLAND POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION)

TABLE 48 SWITZERLAND POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015–2024 (USD MILLION)

TABLE 49 REST OF EUROPE POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

FIGURES LIST

FIGURE 1 EUROPEPOINT-OF-CARE TESTING MARKET SNAPSHOT (2017)

FIGURE 2 EUROPEPOINT-OF-CARE TESTING MARKET BY COUNTRY (2017)

FIGURE 3 EUROPE POINT-OF-CARE TESTING MARKET BY COUNTRY (2016 & 2024)

FIGURE 4 EUROPEPOINT-OF-CARE TESTING MARKET BY PRODUCT TYPE (2017 & 2024)

FIGURE 5 EUROPE POINT-OF-CARE TESTING MARKET: COMPANY SHARE 2016 (%)

Purchase this Market Research Report

REACH OUT TO US

Call us on : +1 888 709 8757

Drop us an email at : info@researchcosmos.com

HAVE A QUESTION?